Thera-SAbDab

BRODALUMAB

>   Structural Summary
TherapeuticBrodalumab
TargetIL17RA
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS
Light ChainEIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2011
INN Year Recommended2012
Companies InvolvedAmgen, AstraZeneca, Bausch Health Companies, Kyowa Hakko Kirin, LEO Pharma
Conditions ApprovedErythrodermic psoriasis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis, Psoriasis
Conditions ActiveSpondylarthritis, Systemic scleroderma
Conditions DiscontinuedAsthma, Crohn's disease, Rheumatoid arthritis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]